Obtained the Australian Phase 1 clinical approval of ACT004 for the treatment of renal fibrosis
2022.03
Us Phase II clinical approval for diffuse midline glioma (DMG) was obtained
2022.01
China Phase II approval for progressive fibrotic interstitial lung disease (including idiopathic pulmonary fibrosis) was obtained
2021.11
Qualify for Rare Diseases in Childhood (RPDD) in the United States
2021.02
Obtained the Australian Phase IIa approval for combined radiotherapy for solid tumor brain metastases
2020.09
China Phase II approval for recurrent glioblastoma was obtained
2020.06
Obtained the approval for Phase IIb/III clinical trial of combined radiotherapy for solid tumor with brain metastases in China
2020.02
After communication with CDE (Drug Evaluation Center of the State Drug Administration) Enter the Chinese phase II clinical trial for the treatment of recurrent GBM
2020.01
The US clinical Phase II approval for the treatment of recurrent GBM was obtained
2019.11
Access to Treatment for PF-ILD (Progressive fibrotic interstitial Lung Disease) Australian clinical Phase II approval
